# OnCo record ependymoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/ependymoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "ependymoma" ;
  schema:name "Ependymoma"@en ;
  schema:alternateName "Childhood ependymoma"@en, "Posterior fossa ependymoma"@en, "Supratentorial ZFTA fusion ependymoma"@en, "Myxopapillary ependymoma"@en ;
  schema:description "Ependymomas grow from the cells lining the fluid spaces of the brain and spinal cord, mostly in children under five. Removing the whole tumour followed by focused radiotherapy controls most cases; molecular groups defined in 2021 behave differently, with posterior fossa group A relapsing often, and there is no approved drug."@en ;
  schema:url <https://onco.cc/cancers/ependymoma/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Ependymoma> ;
  schema:citation <https://www.cancer.gov/types/brain/hp/child-ependymoma-treatment-pdq>, <https://doi.org/10.1016/j.ccell.2015.04.002>, <https://doi.org/10.1200/JCO.18.01765> ;
  onco:tag "nci-coverage", "paediatric", "cns" ;
  onco:related <https://onco.cc/cancers/medulloblastoma/>, <https://onco.cc/cancers/paediatric-low-grade-glioma/>, <https://onco.cc/cancers/atrt/>, <https://onco.cc/cancers/glioblastoma/>, <https://onco.cc/cancers/spinal-cord-tumours/> ;
  onco:technologies <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/technologies/methylation-profiling/>, <https://onco.cc/technologies/mri/>, <https://onco.cc/technologies/survivorship-care-plan/> ;
  onco:targets <https://onco.cc/targets/cdk4-6/> ;
  onco:drugs <https://onco.cc/drugs/vincristine/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/etoposide/> ;
  onco:companies <https://onco.cc/companies/childrens-oncology-group/> ;
  onco:institutions <https://onco.cc/institutions/siop-europe/>, <https://onco.cc/institutions/st-jude/>, <https://onco.cc/institutions/dkfz/> ;
  onco:pathways <https://onco.cc/pathways/epigenetic-reprogramming/>, <https://onco.cc/pathways/inflammation-nfkb/>, <https://onco.cc/pathways/hippo-yap/> ;
  onco:terms <https://onco.cc/terms/late-effects/>, <https://onco.cc/terms/ependymoma-molecular-groups/> ;
  onco:trials <https://onco.cc/trials/pediatric-match/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-rare-cancers/>, <https://onco.cc/bottlenecks/b-survivorship/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-pajtler-cancer-cell/> ;
  onco:pipeline <https://onco.cc/technologies/methylation-profiling/>, <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/trials/pediatric-match/> ;
  onco:standardOfCare <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/technologies/mri/>, <https://onco.cc/trials/acns0121/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/trials/pediatric-match/>, <https://onco.cc/technologies/proton-therapy/> .